5CV.F Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 22:42):

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA)...

Stats
Šios dienos apimtis	26 387.00
Vidutinė apimtis	14 349.00
Rinkos kapitalizacija	480.01M
EPS	€-0.217 ( 2023-09-30 )
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	-1.460
ATR14	€0.0250 (1.16%)

CureVac N.V. Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

CureVac N.V. Finansinės ataskaitos

Annual	2023
Pajamos:	€52.66M
Bruto pelnas:	€-91.08M (-172.97 %)
EPS:	€-1.150

FY	2023
Pajamos:	€52.66M
Bruto pelnas:	€-91.08M (-172.97 %)
EPS:	€-1.150

FY	2022
Pajamos:	€67.42M
Bruto pelnas:	€-116.57M (-172.91 %)
EPS:	€-1.320

FY	2021
Pajamos:	€102.99M
Bruto pelnas:	€-135.21M (-131.28 %)
EPS:	€-2.34

Financial Reports:

No articles found.

CureVac N.V.

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.